From £39,950 per annum with benefits, subject to skills and experience: The Francis Crick Institute: The post holder will help us provide a world class platform to contribute towards key research in collaboration with the Crick scientific community. London (Central), London (Greater)

From £31,675 per annum with benefits, subject to skills and experience: The Francis Crick Institute: The post holder will help us provide a world class platform to contribute towards key research in collaboration with the Crick scientific community. London (Central), London (Greater)

Funding Opportunity PAR-24-084 from the NIH Guide for Grants and Contracts. The goal of this notice of funding opportunity (NOFO) is to support feasibility trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) for conditions that have been identified by NCCIH as high-priority research topics. This funding opportunity is intended to support feasibility clinical trials that provide new information that are scientifically necessary for the planning and conduct of a subsequent clinical efficacy or effectiveness study, pragmatic trial, or dissemination and implementation trial within NCCIHs mission. NCCIH expects that applications to this NOFO will describe the planned future clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent competitive full-scale clinical trial. Under this R34, the data collected should be used to fill gaps in scientific knowledge necessary to develop a competitive full-scale clinical trial, including, but not limited to the following: examining feasibility and acceptability of interventions lacking published data; tailoring or adapting the content or structure of an intervention to a specific population, modality, or setting; refining the intervention to determine the most appropriate frequency or duration; determining feasibility of recruitment, retention, and data collection procedures; refining and assessing the feasibility of protocolized multi-component interventions; or examining acceptability and adherence of control conditions. The subsequent full-scale clinical trial should have the potential to make a significant impact on public health. Prior to submitting to this NOFO, applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact person for the science area of the planned application. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP).

Notice NOT-DC-24-014 from the NIH Guide for Grants and Contracts

Notice NOT-DA-23-048 from the NIH Guide for Grants and Contracts

Notice NOT-AA-24-003 from the NIH Guide for Grants and Contracts

Perform routine analysis of data using the command line: assist with troubleshooting and daily quality control of data and assist researchers with data analysis… $4,649 - $7,500 a month
From University of Washington - Thu, 21 Dec 2023 06:49:37 GMT - View all Seattle, WA jobs

F. Hoffmann-La Roche AG: Bioinformatics , Senior Scientist- Genentech Computational Sciences (gCS) Computational Biology & Translation (CB&T) We seek a highly motivated Sen... South San Francisco, California, United States of America

Funding Opportunity PAR-24-080 from the NIH Guide for Grants and Contracts. This notice of funding opportunity (NOFO) encourages revision applications from currently funded NIH Centers for AIDS Research (CFAR) and Developmental CFARs (D-CFAR) to expand the role of the CFARs and D-CFARs to include additional support and infrastructure for outreach and research related to HIV and HIV-related health disparities in the United States and globally. The goal of the NOFO is aimed towards diversifying and supporting the next generation of HIV/AIDS investigators, and engaging and mentoring these investigators in high-priority HIV/AIDS research.

Funding Opportunity RFA-DA-25-008 from the NIH Guide for Grants and Contracts. HIV infection and substance use are comorbid conditions that bidirectionally and synergistically influence the deleterious outcomes in people who suffer from substance use disorders (SUD). The persistence and transcriptional reactivation of HIV lead to the development of neuropathological complications. Strategies to address viral latency include silencing of HIV transcription and reactivation and clearance. The goal of this initiative is to support research aimed at (1) identification of targets and pathways by which transcriptional activity of HIV can be suppressed in HIV reservoirs including the CNS in people with SUD, and (2) application of emerging small molecule drug discovery approaches to identify novel compounds that can be utilized as pharmacological probes and as drugs to suppress HIV transcription in people with HIV-SUD comorbidity.

Funding Opportunity RFA-DA-25-007 from the NIH Guide for Grants and Contracts. HIV infection and substance use are comorbid conditions that bidirectionally and synergistically influence the deleterious outcomes in people who suffer from substance use disorders (SUD). The persistence and transcriptional reactivation of HIV lead to the development of neuropathological complications. Strategies to address viral latency include silencing of HIV transcription and reactivation and clearance. The goal of this initiative is to support research aimed at (1) identification of targets and pathways by which transcriptional activity of HIV can be suppressed in HIV reservoirs including the CNS in people with SUD, and (2) application of emerging small molecule drug discovery approaches to identify novel compounds that can be utilized as pharmacological probes and as drugs to suppress HIV transcription in people with HIV-SUD comorbidity.

Funding Opportunity RFA-DC-24-007 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) solicits R01 grant applications that propose independent research projects that are within the scientific mission areas of the National Institute on Deafness and Other Communication Disorders (NIDCD). This program is intended to support Early Stage and New Investigators from diverse backgrounds, including those from groups underrepresented in the health-related sciences. Investigators from diverse backgrounds, including those from underrepresented groups (e.g., seeNOT-OD-20-031, Notice of NIHs Interest in Diversity), are eligible to apply. Investigators from categories A-C are particularly encouraged to work with their institutions to apply. Preliminary data are not required for this NOFO. All applications require a letter of affirmation from the applicant institution documenting the Investigators eligibility. Applications that do not include this letter will be administratively withdrawn.

Notice NOT-TW-24-002 from the NIH Guide for Grants and Contracts

Notice NOT-OD-24-050 from the NIH Guide for Grants and Contracts

Notice NOT-GM-24-021 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AI-24-002 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support research that enhances understanding of the mechanisms and management of vaccine and antibiotic drug allergy.

Notice NOT-MH-24-130 from the NIH Guide for Grants and Contracts

Negotiable: Oxford Nanopore Technologies: Oxford Nanopore Technologies is headquartered at the Oxford Science Park outside Oxford, UK, with satellite offices and a commercial presence in many Oxford, England

Notice NOT-CA-24-020 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-24-090 from the NIH Guide for Grants and Contracts. This notice of funding opportuntity (NOFO) encourages applications for investigator-initiated multi site clinical trials (e.g., efficacy, effectiveness, or pragmatic trials) to study the effects of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions), and/or multicomponent interventions that include physical, psychological, and/or nutritional approaches in NCCIH- designated areas of high research priority. Clinical Coordinating Centers (CCC) should develop and implement the proposed fully powered multi-site clinical trial (Phase III and beyond). The objective of a CCC application is to present the scientific rationale and a comprehensive scientific and operational plan for the clinical trial. CCCapplications are expected to describe plans for project management, participant recruitment and retention strategies, performance milestones, scientific conduct, and dissemination of results. CCC applications submitted under this NOFO will utilize a two-phase, milestone-driven cooperative agreement (UG3/UH3) funding mechanism. In addition, an accompanying Data Coordinating Center (DCC) application (U24), submitted under PAR-24-087 proposing a data analysis and data management plan for the clinical project is required. Both a CCC application and a corresponding DCC application need to be submitted simultaneously for consideration by NCCIH. For additional information about the mission, strategic vision, and research priorities of NCCIH, applicants are encouraged to consult the NCCIH website: (https://nccih.nih.gov/about/plans). Applicants are encouraged to contact the appropriate Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this NOFO.